Skip to content

A clinical trial of tumor markers in the clinical application of urothelial carcinoma

A clinical trial of tumor markers in the clinical application of urothelial carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17012810
Enrollment
Unknown
Registered
2017-09-26
Start date
2017-10-16
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial Carcinoma

Interventions

Gold Standard:The clinical diagnostic criteria were based on the results of cases
Index test:BTA(magnetic&#32
NMP22(magnetic&#32
MMP-9&#32
Survivin(magnetic&#32

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Collected from a medical check-up crowd samples, apparent health, routine urine and imaging result is normal, the comprehensive physical examination report, according to standards it is normal for the age level distribution should be about equal to the urothelial carcinoma cases; 2. Collected from outpatient/ward urothelial carcinoma samples, conventional diagnostic process fall off (imaging examination, urine cytology examination and microscopic examination of the bladder, ureteral microscopy) positive decision criteria for pathological diagnosis, and if you have any disease complicated with other interference (such as urinary tract infection, inflammation, etc.), according to the samples into urothelial carcinoma; 3. Collected from outpatient/ward other urothelial carcinoma samples, conventional diagnostic process for other non urothelial carcinoma, according to standards for ages distribution should be about equal to the urothelial carcinoma cases.

Exclusion criteria

Exclusion criteria: 1. Samples of two or more patients with urothelial carcinoma (pyeloneal carcinoma, ureteral carcinoma, bladder cancer); 2. Incomplete samples of the case information, and the information of the positive cases could not identify the pathological results and the sample of tumor staging; 3. Sampling and preservation of improper samples; 4. Samples of pollution; 5. Failed to complete the samples for reasonable reasons; 6. The main investigator of each clinical unit considers any other reason.

Design outcomes

Primary

MeasureTime frame
Sensitivity;specificity;Positive predictive value;Negative predictive value;

Countries

China

Contacts

Public ContactZhiping Wang

Lanzhou University Second Hospital

erywzp@lzu.edu.cn+86 13893131697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026